| Literature DB >> 16398058 |
Alex Roca-Cusachs1, Filippos Triposkiadis.
Abstract
Manidipine is a lipophilic, third-generation, highly vasoselective, dihydropyridine (DHP) calcium channel antagonist, which, when given on a once-daily basis, effectively reduces blood pressure (BP) in patients with mild-to-moderate essential hypertension. Manidipine has a gradual onset and a long duration of action, effectively maintaining reduced BP levels throughout the 24-hour dosing period, and is effective in the long term with no evidence of intolerance. The BP-lowering capacity of manidipine is similar to that of other established DHPs and of angiotensin-converting enzyme inhibitors. Diabetic patients and very elderly patients with mild-to-moderate hypertension also respond favourably to treatment with manidipine. Manidipine has neutral effects on glucose and lipid metabolism and is generally well tolerated. Manidipine thus represents a first-line option for lowering BP in patients with mild-to-moderate hypertension.Entities:
Mesh:
Substances:
Year: 2005 PMID: 16398058 DOI: 10.2165/00003495-200565002-00003
Source DB: PubMed Journal: Drugs ISSN: 0012-6667 Impact factor: 9.546